Scientists collaborate to develop E coli vaccine

A deal has been reached to develop a commercial vaccine for a type of E coli in cattle that can become life-threatening for people.

The specific type of bacteria found in cows – O157:H7 – can cause fatal foodborne illness in humans through eating contaminated livestock produce.

This experimental vaccine has been developed to limit “shedding” and transmission between cattle.

It is believed the biggest market for the commercial drug will be in the US and South America, although worldwide consumption of contaminated food causes up to 10 cases per 100,000 people.

Although the bacteria does not harm the cattle, farmers will be encouraged to vaccinate animals against infection.

Tom Mcneilly, from the Moredun Research Institute in Penicuik, said: “E coli O157:H7 is prevalent in the US, as well as parts of South America and Europe, including the UK.

“To be commercially viable, one has to show the vaccine works in their systems.

“We have a collaboration with the USDA (United States Department of Agriculture) and they’ve agreed to run a field trial in Nebraska with the help of Roslin Technologies.”

Roslin Technologies – the commercial arm of the Roslin Institute at Edinburgh University – has signed an agreement with the Moredun Research Institute, Scotland’s Rural College and the Roslin Institute for the research.

Researchers will work to see whether the vaccine prevents passing of the bacteria in cattle faeces and is viable for commercial use.